ATE316385T1 - Zusammensetzungen zur behandlung und vorbeugung von atherosklerose - Google Patents

Zusammensetzungen zur behandlung und vorbeugung von atherosklerose

Info

Publication number
ATE316385T1
ATE316385T1 AT95921563T AT95921563T ATE316385T1 AT E316385 T1 ATE316385 T1 AT E316385T1 AT 95921563 T AT95921563 T AT 95921563T AT 95921563 T AT95921563 T AT 95921563T AT E316385 T1 ATE316385 T1 AT E316385T1
Authority
AT
Austria
Prior art keywords
treatment
atherosclerosis
prevention
compositions
selectin
Prior art date
Application number
AT95921563T
Other languages
English (en)
Inventor
Denisa D Wagner
Robert C Johnson
Original Assignee
Cbr Inst For Biomed Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbr Inst For Biomed Res Inc filed Critical Cbr Inst For Biomed Res Inc
Application granted granted Critical
Publication of ATE316385T1 publication Critical patent/ATE316385T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
AT95921563T 1994-06-03 1995-06-01 Zusammensetzungen zur behandlung und vorbeugung von atherosklerose ATE316385T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25366394A 1994-06-03 1994-06-03
US37779895A 1995-01-24 1995-01-24

Publications (1)

Publication Number Publication Date
ATE316385T1 true ATE316385T1 (de) 2006-02-15

Family

ID=26943460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921563T ATE316385T1 (de) 1994-06-03 1995-06-01 Zusammensetzungen zur behandlung und vorbeugung von atherosklerose

Country Status (6)

Country Link
EP (1) EP0759781B1 (de)
JP (1) JPH10504527A (de)
AT (1) ATE316385T1 (de)
CA (1) CA2191577C (de)
DE (1) DE69534761T2 (de)
WO (1) WO1995033484A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1325123A4 (de) * 2000-09-12 2004-07-21 Inst Genetics Llc Stenose- bzw. restenosehemmung durch p-selectin-antagonisten
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
WO2008069999A2 (en) * 2006-12-01 2008-06-12 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
EP3261675A1 (de) * 2015-02-25 2018-01-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Sialylierungserhöhende therapien für erkrankungen im zusammenhang mit oxidativem stress

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575557A1 (de) * 1991-03-11 1993-12-29 New England Medical Center Verfahren zur hemmung von padgem-vermittelter interaktionen unter verwendung von einer 2,6-sialinsäure
EP0652897A4 (de) * 1992-05-28 1995-09-20 Centocor Inc Peptid inhibitoren gegen die selektinbindung.
EP0656904A1 (de) * 1992-05-28 1995-06-14 Centocor Inc. Peptidinhibitoren für die selectin-bindung
WO1994005269A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of selectin binding
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
US5559103A (en) * 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors

Also Published As

Publication number Publication date
JPH10504527A (ja) 1998-05-06
CA2191577C (en) 2010-03-16
DE69534761T2 (de) 2006-10-12
EP0759781A4 (de) 2000-12-06
CA2191577A1 (en) 1995-12-14
DE69534761D1 (de) 2006-04-13
EP0759781A1 (de) 1997-03-05
WO1995033484A1 (en) 1995-12-14
EP0759781B1 (de) 2006-01-25

Similar Documents

Publication Publication Date Title
ATE173630T1 (de) Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
DE69719408D1 (de) Verwendung von Strontiumsälze zur Behandlung von Arthrose
DE69429369D1 (de) Verfahren und mittel zur behandlung abnormaler zustände des epitheliums von körperöffnungen
ATE20185T1 (de) Mittel zur verhuetung und behandlung von leberund nierenkrankheiten.
GEP20033044B (en) Method for Treating Atherosclerosis
DK0880350T3 (da) Behandling af dissemineret sklerose
DE69733611D1 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
DE69331265D1 (de) Verbindungen zur behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
DE69434511D1 (de) Botulinumtoxin zur Behandlung von Dystonie
EP0695224A4 (de) Zusammensetzungen und verfahren zur behandlung von abfällen
MX9304638A (es) Composicion para tratar e inhibir las ulceras gastricas y duodenales.
DE69222735D1 (de) Zusammensetzung und Verfahren zur Behandlung von Kühlwasser
DE69940508D1 (de) Verfahren und zusammensetzung zur behandlung epidermaler irritationen und infektionen
DE69424537D1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
DE69404854D1 (de) Verfahren zur behandlung von androgener lopecia mit 5-alpha-reduktase-hemmern
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DE69429101D1 (de) Verbindungen und zusammensetzungen zur behandlung von allergien und entzündungen
ATE316385T1 (de) Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
IL72620A (en) 2-hydroxy-benzoyl peroxide and compositions for treating acne
PL327818A1 (en) Novel medical application of ace inhibitor in treating dipeptic symptoms
DE59710660D1 (de) Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
NO982582L (no) Fremgangsmaate for behandling av smerte

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties